Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference

Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference

PR Newswire

BOULDER, Colo., May 30, 2018 /PRNewswire/ -- Array BioPharma Inc. ARRY today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2018 Global Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   

Event:

Jefferies 2018 Global Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Wednesday, June 6, 2018

Time:

2 p.m. Eastern Time

Webcast:

http://wsw.com/webcast/jeff113/arry/

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions. Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics). For more information on Array, please go to www.arraybiopharma.com.

CONTACT:       

Andrea N. Flynn, Ph.D.

Senior Director, Investor Relations & Corporate Communications

(303) 381-6600

ir@arraybiopharma.com

Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-jefferies-2018-global-healthcare-conference-300655974.html

SOURCE Array BioPharma

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press ReleasesConference Call Announcementstrade shows
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!